Analyst Reco. Exagen Inc.

Equities

XGN

US30068X1037

Delayed Nasdaq Other stock markets 09:30:00 2024-04-26 am EDT			5-day change	1st Jan Change
1.41 ^USD	0.00%		+2.92%	-29.15%

Mar. 18	Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating	23-03-22	MT
BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating	22-11-17	MT
Canaccord Genuity Cuts Price Target on Exagen to $7 From $8, Affirms Buy Rating	22-11-15	MT
KeyBanc Downgrades Exagen to Sector Weight From Overweight, Citing 'Uncertain Test Pricing Process'	22-08-05	MT
KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating	22-05-13	MT
KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating	22-03-25	MT
Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating	22-03-23	MT
KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating	21-11-11	MT
EXAGEN : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating	21-08-10	MT
EXAGEN : Canaccord Genuity Initiates Exagen at Buy Rating With $25 Price Target	21-04-15	MT
EXAGEN : KeyBanc Initiates Exagen at Overweight with $32 Price Target	20-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer